Last updated on February 2019

Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI


Brief description of study

This study is designed to provide long-term CDZ173 treatment, a selective PI3K inhibitor, to the patients with genetically activated PI3K, i.e., patients with APDS/PASLI who participated in the CCDZ173X2201 study or who were treated previously with PI3K inhibitors other than CDZ173. The study is open-label designed to establish the long-term safety, tolerability, efficay and pharmacokinetics of CDZ173 in the target population.

Clinical Study Identifier: NCT02859727

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
Rotterdam, Netherlands
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.